Therapeutic Effect of Hydrogen Sulfide-Releasing L-Dopa Derivative ACS84 on 6-OHDA-Induced Parkinson's Disease Rat Model

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Xie, Li ^a   Hu, Li Fang ^b   Teo, Xing Qi ^a   Tiong, Chi Xin ^a   Tazzari, Valerio ^c   Sparatore, Anna ^c   Soldato, Piero Del ^d   Dawe, Gavin Stewart ^a   Bian, Jin Song ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SOOCHOW UNIVERSITY   (China)

^c UNIVERSITY OF MILAN   (Italy)

^d CTG Pharma   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACS 84; ANTIPARKINSON AGENT; BISULFITE; DOPAMINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; HEME OXYGENASE 1; LEVODOPA; MALONALDEHYDE; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR NRF2; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG STRUCTURE; GCL GENE; GENE; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HO 1 GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; NRF2 GENE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; ANTIPARKINSON AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DISULFIDES; DOPAMINE; DOPAMINERGIC NEURONS; ENZYME INDUCTION; GENE EXPRESSION; GLUTAMATE-CYSTEINE LIGASE; HEME OXYGENASE-1; HUMANS; LEVODOPA; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; RESPONSE ELEMENTS; SUBSTANTIA NIGRA;

ANIMALIA; RATTUS;

EID: 84875698446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060200     Document Type: Article

References (48)

1. Lang AE, Lozano AM, (1998) Parkinson's disease. Second of two parts. N Engl J Med 339: 1130-1143.
2. Lang AE, Lozano AM, (1998) Parkinson's disease. First of two parts. N Engl J Med 339: 1044-1053.
3. Moore DJ, West AB, Dawson VL, Dawson TM, (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28: 57-87.
4. Nagatsua T, Sawadab M, (2009) L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord 15Suppl 1: S3-8.
5. Weiner WJ, (2006) Levodopa-toxic or neuroprotective? Nat Clin Pract Neurol 2: 518-519.
6. Schapira AH, (2008) The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Mov Disord 23Suppl 3: S515-520.
7. Jankovic J, Stacy M, (2007) Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21: 677-692.
8. Hattoria N, Wanga M, Taka H, Fujimura T, Yoritaka A, et al. (2009) Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 15Suppl 1: S35-38.
9. Minelli A, Conte C, Prudenzi E, Cacciatore I, Cornacchia C, et al. (2010) N-Acetyl-L-Methionyl-L-Dopa-Methyl Ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity. Free Radical Biology and Medicine 49: 31-39.
10. Mytilineou C, Han SK, Cohen G, (1993) Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 61: 1470-1478.
11. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW, (2003) Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304: 792-800.
12. Abe K, Kimura H, (1996) The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16: 1066-1071.
13. Kimura H, (2000) Hydrogen sulfide induces cyclic AMP and modulates the NMDA receptor. Biochem Biophys Res Commun 267: 129-133.
14. Lee SW, Hu YS, Hu LF, Lu Q, Dawe GS, et al. (2006) Hydrogen sulphide regulates calcium homeostasis in microglial cells. Glia 54: 116-124.
15. Nagai Y, Tsugane M, Oka J, Kimura H, (2004) Hydrogen sulfide induces calcium waves in astrocytes. FASEB J 18: 557-559.
16. Kimura Y, Goto Y, Kimura H, (2010) Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid Redox Signal 12: 1-13.
17. Kimura Y, Kimura H, (2004) Hydrogen sulfide protects neurons from oxidative stress. FASEB J 18: 1165-1167.
18. Hu LF, Wong PT, Moore PK, Bian JS, (2007) Hydrogen sulfide attenuates lipopolysaccharide-induced inflammation by inhibition of p38 mitogen-activated protein kinase in microglia. J Neurochem 100: 1121-1128.
19. Liu YY, Bian JS, (2010) Hydrogen sulfide protects amyloid-beta induced cell toxicity in microglia. J Alzheimers Dis 22: 1189-1200.
20. Lu M, Hu LF, Hu G, Bian JS, (2008) Hydrogen sulfide protects astrocytes against H(2)O(2)-induced neural injury via enhancing glutamate uptake. Free Radic Biol Med 45: 1705-1713.
21. Hu LF, Lu M, Wu ZY, Wong PT, Bian JS, (2009) Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function. Mol Pharmacol 75: 27-34.
22. Tiong CX, Lu M, Bian JS, (2010) Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway. Br J Pharmacol 161: 467-480.
23. Hu LF, Lu M, Tiong CX, Dawe GS, Hu G, et al. (2010) Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. Aging Cell 9: 135-146.
24. Kida K, Yamada M, Tokuda K, Marutani E, Kakinohana M, et al. (2010) Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson's disease. Antioxid Redox Signal.
25. Lee M, Tazzari V, Giustarini D, Rossi R, Sparatore A, et al. (2010) Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J Biol Chem 285: 17318-17328.
26. Sparatore A, Santus G, Giustarini D, Rossi R, Del Soldato P, (2011) Therapeutic potential of new hydrogen sulfide-releasing hybrids. Expert Review of Clinical Pharmacology 4: 109-121.
27. Liu YY, Sparatore A, Del Soldato P, Bian JS (2011) ACS84, a novel hydrogen sulfide-releasing compound, protects against amyloid beta-induced cell cytotoxicity. Neurochem Int.
28. Bove J, Prou D, Perier C, Przedborski S, (2005) Toxin-induced models of Parkinson's disease. NeuroRx 2: 484-494.
29. Tolwani RJ, Jakowec MW, Petzinger GM, Green S, Waggie K, (1999) Experimental models of Parkinson's disease: insights from many models. Lab Anim Sci 49: 363-371.
30. Li J, Johnson JA, (2002) Time-dependent changes in ARE-driven gene expression by use of a noise-filtering process for microarray data. Physiol Genomics 9: 137-144.
31. Kutty RK, Kutty G, Nagineni CN, Hooks JJ, Chader GJ, et al. (1994) RT-PCR assay for heme oxygenase-1 and heme oxygenase-2: a sensitive method to estimate cellular oxidative damage. Ann N Y Acad Sci 738: 427-430.
32. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S, (2005) S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28: 195-204.
33. Zhu W, Xie W, Pan T, Xu P, Fridkin M, et al. (2007) Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21: 3835-3844.
34. Double KL, Reyes S, Werry EL, Halliday GM, (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol 92: 316-329.
35. Xu ZS, Wang XY, Xiao DM, Hu LF, Lu M, et al. (2011) Hydrogen sulfide protects MC3T3-E1 osteoblastic cells against H(2)O(2)-induced oxidative damage-implications for the treatment of osteoporosis. Free Radic Biol Med.
36. Taniguchi S, Kang L, Kimura T, Niki I, (2011) Hydrogen sulphide protects mouse pancreatic beta-cells from cell death induced by oxidative stress, but not by endoplasmic reticulum stress. Br J Pharmacol 162: 1171-1178.
37. Cao TT, Ma L, Kandpal G, Warren L, Hess JF, et al. (2005) Increased nuclear factor-erythroid 2 p45-related factor 2 activity protects SH-SY5Y cells against oxidative damage. J Neurochem 95: 406-417.
38. Alam J, Cook JL, (2003) Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway. Curr Pharm Des 9: 2499-2511.
39. Huang HC, Nguyen T, Pickett CB, (2000) Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc Natl Acad Sci U S A 97: 12475-12480.
40. Nakaso K, Yano H, Fukuhara Y, Takeshima T, Wada-Isoe K, et al. (2003) PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. FEBS Lett 546: 181-184.
41. Krishnan N, Fu C, Pappin DJ, Tonks NK, (2011) H2S-Induced sulfhydration of the phosphatase PTP1B and its role in the endoplasmic reticulum stress response. Sci Signal 4: ra86.
42. Mustafa AK, Gadalla MM, Sen N, Kim S, Mu W, et al. (2009) H2S signals through protein S-sulfhydration. Sci Signal 2: ra72.
43. Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, et al. (2011) Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ Res 109: 1259-1268.
44. Chakraborty A, Werner JK Jr, Koldobskiy MA, Mustafa AK, Juluri KR, et al. (2011) Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. Proc Natl Acad Sci U S A 108: 2205-2209.
45. Sen N, Paul BD, Gadalla MM, Mustafa AK, Sen T, et al. (2012) Hydrogen sulfide-linked sulfhydration of NF-kappaB mediates its antiapoptotic actions. Mol Cell 45: 13-24.
46. Tao BB, Liu SY, Zhang CC, Fu W, Cai WJ, et al. (2012) VEGFR2 functions as an H2S-targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells. Antioxid Redox Signal.
47. Yang G, Zhao K, Ju Y, Mani S, Cao Q, et al. (2012) Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. Antioxid Redox Signal.
48. Drukarch B, Flier J, Jongenelen CA, Andringa G, Schoffelmeer AN, (2006) The antioxidant anethole dithiolethione inhibits monoamine oxidase-B but not monoamine oxidase A activity in extracts of cultured astrocytes. J Neural Transm 113: 593-598.